Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress
Summary Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end‐stage renal disease. Many factors are involved in premature ageing in CKD, including hormo...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental pharmacology & physiology 2017-12, Vol.44 (S1), p.70-77 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | S1 |
| container_start_page | 70 |
| container_title | Clinical and experimental pharmacology & physiology |
| container_volume | 44 |
| creator | Hirakawa, Yosuke Jao, Tzu‐Ming Inagi, Reiko |
| description | Summary
Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end‐stage renal disease. Many factors are involved in premature ageing in CKD, including hormonal imbalance, glycative stress, nitrogenous metabolites, and oxidative stress. Of these, the most important role in premature ageing in CKD is played by glycative stress, namely a massive and unfavourable glycation state, since the kidney is responsible for the clearance of advanced glycation endproducts (AGEs). In an animal model, overexpression of glyoxalase I (GLO‐1), a detoxifier of AGEs, has been found to alleviate premature ageing in the kidney and vessels. Both lifestyle changes and drug therapy have shown promise in overcoming premature ageing. Promising drug therapies include a GLO‐1 activator and an absorbent against glycotoxin and nitrogenous metabolites. |
| doi_str_mv | 10.1111/1440-1681.12777 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1895272957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979949925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4127-24781a77e8f4e0357664add222ce7aebbe23ced506fb8c3be2e8f8b72850458a3</originalsourceid><addsrcrecordid>eNqFkT1P5DAQhi0EguWjpkOWaCgI2I4dOyVaAXcSEhRHbTnOZGPIxsFOWOXfn_eWo7jmphnN6JlXM-8gdE7JDU1xSzknGS0UvaFMSrmHFt-dfbQgOREZVZIcoeMY3wghghT5ITpiiheyIPkCDS9mbP3QztH5zq9mbPoajy0EM8A0Ohuxb_AQYG3GKQA2K3D9Crse2zb43ln87uoeZly7CCbCNd64scUGN95OabbHq262ZnSfgOMYIMZTdNCYLsLZVz5Brw_3v5Y_sqfnx5_Lu6fM8nRKxrhU1EgJquFAciGLgpu6ZoxZkAaqClhuoU73NJWyeSoTqSrJlCBcKJOfoKud7hD8xwRx1GsXLXSd6cFPUVNVCiZZKWRCL_9B3_wU-rSdpqUsS16WTCTqdkfZ4GMM0OghuLUJs6ZEb5-ht9brrfX6zzPSxMWX7lStof7m_7qfALEDNq6D-X96enn_shP-DQsVlKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979949925</pqid></control><display><type>article</type><title>Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress</title><source>Wiley Blackwell Single Titles</source><creator>Hirakawa, Yosuke ; Jao, Tzu‐Ming ; Inagi, Reiko</creator><creatorcontrib>Hirakawa, Yosuke ; Jao, Tzu‐Ming ; Inagi, Reiko</creatorcontrib><description>Summary
Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end‐stage renal disease. Many factors are involved in premature ageing in CKD, including hormonal imbalance, glycative stress, nitrogenous metabolites, and oxidative stress. Of these, the most important role in premature ageing in CKD is played by glycative stress, namely a massive and unfavourable glycation state, since the kidney is responsible for the clearance of advanced glycation endproducts (AGEs). In an animal model, overexpression of glyoxalase I (GLO‐1), a detoxifier of AGEs, has been found to alleviate premature ageing in the kidney and vessels. Both lifestyle changes and drug therapy have shown promise in overcoming premature ageing. Promising drug therapies include a GLO‐1 activator and an absorbent against glycotoxin and nitrogenous metabolites.</description><identifier>ISSN: 0305-1870</identifier><identifier>EISSN: 1440-1681</identifier><identifier>DOI: 10.1111/1440-1681.12777</identifier><identifier>PMID: 28467603</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Advanced glycosylation end products ; Aging ; Blood vessels ; Cardiovascular diseases ; chronic kidney disease ; Drug therapy ; End-stage renal disease ; GLO‐1 ; glycative stress ; Glycosylation ; Health risks ; indoxyl sulphate ; Kidney diseases ; Lactoylglutathione lyase ; Metabolites ; Oxidative stress ; Pathophysiology ; phosphorus ; premature ageing ; Public health</subject><ispartof>Clinical and experimental pharmacology & physiology, 2017-12, Vol.44 (S1), p.70-77</ispartof><rights>2017 John Wiley & Sons Australia, Ltd</rights><rights>2017 John Wiley & Sons Australia, Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4127-24781a77e8f4e0357664add222ce7aebbe23ced506fb8c3be2e8f8b72850458a3</citedby><cites>FETCH-LOGICAL-c4127-24781a77e8f4e0357664add222ce7aebbe23ced506fb8c3be2e8f8b72850458a3</cites><orcidid>0000-0001-9238-650X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1440-1681.12777$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1440-1681.12777$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28467603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirakawa, Yosuke</creatorcontrib><creatorcontrib>Jao, Tzu‐Ming</creatorcontrib><creatorcontrib>Inagi, Reiko</creatorcontrib><title>Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress</title><title>Clinical and experimental pharmacology & physiology</title><addtitle>Clin Exp Pharmacol Physiol</addtitle><description>Summary
Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end‐stage renal disease. Many factors are involved in premature ageing in CKD, including hormonal imbalance, glycative stress, nitrogenous metabolites, and oxidative stress. Of these, the most important role in premature ageing in CKD is played by glycative stress, namely a massive and unfavourable glycation state, since the kidney is responsible for the clearance of advanced glycation endproducts (AGEs). In an animal model, overexpression of glyoxalase I (GLO‐1), a detoxifier of AGEs, has been found to alleviate premature ageing in the kidney and vessels. Both lifestyle changes and drug therapy have shown promise in overcoming premature ageing. Promising drug therapies include a GLO‐1 activator and an absorbent against glycotoxin and nitrogenous metabolites.</description><subject>Advanced glycosylation end products</subject><subject>Aging</subject><subject>Blood vessels</subject><subject>Cardiovascular diseases</subject><subject>chronic kidney disease</subject><subject>Drug therapy</subject><subject>End-stage renal disease</subject><subject>GLO‐1</subject><subject>glycative stress</subject><subject>Glycosylation</subject><subject>Health risks</subject><subject>indoxyl sulphate</subject><subject>Kidney diseases</subject><subject>Lactoylglutathione lyase</subject><subject>Metabolites</subject><subject>Oxidative stress</subject><subject>Pathophysiology</subject><subject>phosphorus</subject><subject>premature ageing</subject><subject>Public health</subject><issn>0305-1870</issn><issn>1440-1681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkT1P5DAQhi0EguWjpkOWaCgI2I4dOyVaAXcSEhRHbTnOZGPIxsFOWOXfn_eWo7jmphnN6JlXM-8gdE7JDU1xSzknGS0UvaFMSrmHFt-dfbQgOREZVZIcoeMY3wghghT5ITpiiheyIPkCDS9mbP3QztH5zq9mbPoajy0EM8A0Ohuxb_AQYG3GKQA2K3D9Crse2zb43ln87uoeZly7CCbCNd64scUGN95OabbHq262ZnSfgOMYIMZTdNCYLsLZVz5Brw_3v5Y_sqfnx5_Lu6fM8nRKxrhU1EgJquFAciGLgpu6ZoxZkAaqClhuoU73NJWyeSoTqSrJlCBcKJOfoKud7hD8xwRx1GsXLXSd6cFPUVNVCiZZKWRCL_9B3_wU-rSdpqUsS16WTCTqdkfZ4GMM0OghuLUJs6ZEb5-ht9brrfX6zzPSxMWX7lStof7m_7qfALEDNq6D-X96enn_shP-DQsVlKQ</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Hirakawa, Yosuke</creator><creator>Jao, Tzu‐Ming</creator><creator>Inagi, Reiko</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9238-650X</orcidid></search><sort><creationdate>201712</creationdate><title>Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress</title><author>Hirakawa, Yosuke ; Jao, Tzu‐Ming ; Inagi, Reiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4127-24781a77e8f4e0357664add222ce7aebbe23ced506fb8c3be2e8f8b72850458a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Advanced glycosylation end products</topic><topic>Aging</topic><topic>Blood vessels</topic><topic>Cardiovascular diseases</topic><topic>chronic kidney disease</topic><topic>Drug therapy</topic><topic>End-stage renal disease</topic><topic>GLO‐1</topic><topic>glycative stress</topic><topic>Glycosylation</topic><topic>Health risks</topic><topic>indoxyl sulphate</topic><topic>Kidney diseases</topic><topic>Lactoylglutathione lyase</topic><topic>Metabolites</topic><topic>Oxidative stress</topic><topic>Pathophysiology</topic><topic>phosphorus</topic><topic>premature ageing</topic><topic>Public health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirakawa, Yosuke</creatorcontrib><creatorcontrib>Jao, Tzu‐Ming</creatorcontrib><creatorcontrib>Inagi, Reiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental pharmacology & physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirakawa, Yosuke</au><au>Jao, Tzu‐Ming</au><au>Inagi, Reiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress</atitle><jtitle>Clinical and experimental pharmacology & physiology</jtitle><addtitle>Clin Exp Pharmacol Physiol</addtitle><date>2017-12</date><risdate>2017</risdate><volume>44</volume><issue>S1</issue><spage>70</spage><epage>77</epage><pages>70-77</pages><issn>0305-1870</issn><eissn>1440-1681</eissn><abstract>Summary
Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end‐stage renal disease. Many factors are involved in premature ageing in CKD, including hormonal imbalance, glycative stress, nitrogenous metabolites, and oxidative stress. Of these, the most important role in premature ageing in CKD is played by glycative stress, namely a massive and unfavourable glycation state, since the kidney is responsible for the clearance of advanced glycation endproducts (AGEs). In an animal model, overexpression of glyoxalase I (GLO‐1), a detoxifier of AGEs, has been found to alleviate premature ageing in the kidney and vessels. Both lifestyle changes and drug therapy have shown promise in overcoming premature ageing. Promising drug therapies include a GLO‐1 activator and an absorbent against glycotoxin and nitrogenous metabolites.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28467603</pmid><doi>10.1111/1440-1681.12777</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9238-650X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-1870 |
| ispartof | Clinical and experimental pharmacology & physiology, 2017-12, Vol.44 (S1), p.70-77 |
| issn | 0305-1870 1440-1681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1895272957 |
| source | Wiley Blackwell Single Titles |
| subjects | Advanced glycosylation end products Aging Blood vessels Cardiovascular diseases chronic kidney disease Drug therapy End-stage renal disease GLO‐1 glycative stress Glycosylation Health risks indoxyl sulphate Kidney diseases Lactoylglutathione lyase Metabolites Oxidative stress Pathophysiology phosphorus premature ageing Public health |
| title | Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathophysiology%20and%20therapeutics%20of%20premature%20ageing%20in%20chronic%20kidney%20disease,%20with%20a%20focus%20on%20glycative%20stress&rft.jtitle=Clinical%20and%20experimental%20pharmacology%20&%20physiology&rft.au=Hirakawa,%20Yosuke&rft.date=2017-12&rft.volume=44&rft.issue=S1&rft.spage=70&rft.epage=77&rft.pages=70-77&rft.issn=0305-1870&rft.eissn=1440-1681&rft_id=info:doi/10.1111/1440-1681.12777&rft_dat=%3Cproquest_cross%3E1979949925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979949925&rft_id=info:pmid/28467603&rfr_iscdi=true |